OR WAIT null SECS
A year after its merger with DSM Pharmaceutical Products, Patheon announces that it has filed an IPO.
Patheon announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined, the company reports in a statement.
J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering.
In March 2014, Patheon completed its $2.65 billion merger with DSM Pharmaceutical Products (DPP) to form DPx.
In April 2015, Patheon completed the acquisition of IRIX Pharmaceuticals, a Florence, SC company that specializes in API development and manufacturing. This follows the March 2015 acquisition of Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving drug bioavailability.